Trial Profile

Open-Label, Randomised, Active Controlled, Multi-Centre Ph 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Acute HIT

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 11 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Danaparoid sodium (Primary) ; Argatroban
Indications Heparin-induced thrombocytopenia and thrombosis syndrome
Focus Registrational; Therapeutic Use
Acronyms HITSOVA
Sponsors Aspen Pharmacare

Most Recent Events

06 Dec 2022 Status changed from active, no longer recruiting to discontinued.
14 Jul 2022 This trial has been discontinued in Czechia (end date of the trial : 10-Jun-2022), according to European Clinical Trials Database record.
07 Jul 2022 This trial has been discontinued in France (Date of the global end of the trial : 10-Jun-2022), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com